141 related articles for article (PubMed ID: 28406063)
1. Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
Klauser AM; Wiebenga OT; Eijlers AJ; Schoonheim MM; Uitdehaag BM; Barkhof F; Pouwels PJ; Geurts JJ
Mult Scler; 2018 Apr; 24(4):491-500. PubMed ID: 28406063
[TBL] [Abstract][Full Text] [Related]
2. Association of Cortical Lesions With Regional Glutamate, GABA,
Madsen MA; Považan M; Wiggermann V; Lundell H; Blinkenberg M; Romme Christensen J; Sellebjerg F; Siebner HR
Neurology; 2024 Jul; 103(1):e209543. PubMed ID: 38870443
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions.
Gaitán MI; Shea CD; Evangelou IE; Stone RD; Fenton KM; Bielekova B; Massacesi L; Reich DS
Ann Neurol; 2011 Jul; 70(1):22-9. PubMed ID: 21710622
[TBL] [Abstract][Full Text] [Related]
4. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
Sartori A; Abdoli M; Freedman MS
J Neurol; 2017 Jun; 264(6):1068-1075. PubMed ID: 28417192
[TBL] [Abstract][Full Text] [Related]
5. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis.
Selmaj I; Cichalewska M; Namiecinska M; Galazka G; Horzelski W; Selmaj KW; Mycko MP
Ann Neurol; 2017 May; 81(5):703-717. PubMed ID: 28411393
[TBL] [Abstract][Full Text] [Related]
6. Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
Morandi E; Tarlinton RE; Tanasescu R; Gran B
Mult Scler; 2017 Jul; 23(8):1050-1055. PubMed ID: 28406354
[TBL] [Abstract][Full Text] [Related]
7. Seasonal variation in multiple sclerosis relapse.
Harding K; Tilling K; MacIver C; Willis M; Joseph F; Ingram G; Hirst C; Wardle M; Pickersgill T; Ben-Shlomo Y; Robertson N
J Neurol; 2017 Jun; 264(6):1059-1067. PubMed ID: 28424900
[TBL] [Abstract][Full Text] [Related]
8. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
9. In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
Kilsdonk ID; Schoonheim M; Wattjes MP
Mult Scler; 2017 Jul; 23(8):1169-1171. PubMed ID: 28417656
[No Abstract] [Full Text] [Related]
10. A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
Kolber P; Droby A; Roebroeck A; Goebel R; Fleischer V; Groppa S; Zipp F
Mult Scler; 2017 Jul; 23(8):1167-1169. PubMed ID: 28417657
[TBL] [Abstract][Full Text] [Related]
11. Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
Meijer KA; Eijlers AJC; Douw L; Uitdehaag BMJ; Barkhof F; Geurts JJG; Schoonheim MM
Neurology; 2017 May; 88(22):2107-2114. PubMed ID: 28468841
[TBL] [Abstract][Full Text] [Related]
12. FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?
Campion T; Smith RJP; Altmann DR; Brito GC; Turner BP; Evanson J; George IC; Sati P; Reich DS; Miquel ME; Schmierer K
Eur Radiol; 2017 Oct; 27(10):4257-4263. PubMed ID: 28409356
[TBL] [Abstract][Full Text] [Related]
13. Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis.
Petracca M; Saiote C; Bender HA; Arias F; Farrell C; Magioncalda P; Martino M; Miller A; Northoff G; Lublin F; Inglese M
Sci Rep; 2017 Apr; 7():46411. PubMed ID: 28429774
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis broke my heart.
Androdias G; Bernard E; Biotti D; Collongues N; Durand-Dubief F; Pique J; Sanchez I; Delmas C; Ninet J; Marignier R; Vukusic S
Ann Neurol; 2017 May; 81(5):754-758. PubMed ID: 28437859
[TBL] [Abstract][Full Text] [Related]
15. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.
Merkel B; Butzkueven H; Traboulsee AL; Havrdova E; Kalincik T
Autoimmun Rev; 2017 Jun; 16(6):658-665. PubMed ID: 28428119
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.
Karamita M; Barnum C; Möbius W; Tansey MG; Szymkowski DE; Lassmann H; Probert L
JCI Insight; 2017 Apr; 2(8):. PubMed ID: 28422748
[TBL] [Abstract][Full Text] [Related]
17. T Cell-Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity.
Hohlfeld R; Steinman L
J Immunol; 2017 May; 198(9):3381-3383. PubMed ID: 28416715
[No Abstract] [Full Text] [Related]
18. Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study.
Tóth E; Szabó N; Csete G; Király A; Faragó P; Spisák T; Bencsik K; Vécsei L; Kincses ZT
Front Neuroanat; 2017; 11():23. PubMed ID: 28424595
[No Abstract] [Full Text] [Related]
19. Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis.
Castellaro M; Magliozzi R; Palombit A; Pitteri M; Silvestri E; Camera V; Montemezzi S; Pizzini FB; Bertoldo A; Reynolds R; Monaco S; Calabrese M
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1087-1095. PubMed ID: 28408633
[TBL] [Abstract][Full Text] [Related]
20. Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.
McNamara C; Sugrue G; Murray B; MacMahon PJ
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1664-1671. PubMed ID: 28408630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
